Biocartis Group NV (CHIX:BCARTB) Land And Improvements : €0.00 Mil (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Biocartis Group NV Land And Improvements?

Biocartis Group NV's land and improvements for the quarter that ended in Jun. 2023 was €0.00 Mil.

Biocartis Group NV Land And Improvements Historical Data

The historical data trend for Biocartis Group NV's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocartis Group NV Land And Improvements Chart

Biocartis Group NV Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Land And Improvements

Get a 7-Day Free Trial

Biocartis Group NV Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Biocartis Group NV Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Biocartis Group NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocartis Group NV (CHIX:BCARTb) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

Generaal de Wittelaan 11 B, Mechelen, BEL, 2800

Website

https://www.biocartis.com

Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an MDx Idylla molecular diagnostic system for oncology and infectious disease segments. Its products include EGFR mutation assay, BRAF mutation test, NRAS mutation test, respiratory panel, etc. The firm derives the majority of its revenues from product sales.

Biocartis Group NV Headlines

No Headlines